Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
NCT01633060 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2019-01-30 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ESR1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-12-09Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Placebo (NCT04191499)
- 2019-08-07Results posted on the registry: Canadian Cancer Trials Group, Palbociclib 100mg + Palbociclib 125mg (NCT02630693)
- 2019-01-03Results posted on the registry: Dana-Farber Cancer Institute, Fulvestrant + Ganetespib (NCT01560416)
- 2018-10-17Results posted on the registry: AstraZeneca, AZD2014 + Fulvestrant (NCT01597388)
- 2018-03-13Results posted on the registry: Eli Lilly and Company, Abemaciclib + Fulvestrant (NCT02107703)
- 2018-02-20Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2018-02-08Phase 3 first posted: Borstkanker Onderzoek Groep, CDK 4/6 inhibitor + Non-Steroidal Aromatase Inhibitor (NCT03425838)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision